Skip to content
Head to head

Nuvation Bio vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NUVB · VRTX

Updated 10 minutes ago

1-year performance, rebased to 100

NUVB -18.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
NUVBVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price3.80515.02
Change today-0.26%-1.08%
1-year return-45.8%+22.0%
Market cap$1.34B$130.58B
52-week range3.71 – 9.75412.27 – 568.67
Valuation
P/E (TTM)-9.7433.14
P/E percentile, own 5-yr range23rd99th
P/B5.886.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.6015.32
Net profit (TTM)$-211.81M$3.88B
Revenue (TTM)$201.73M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+242.6%+11.8%
Gross margin85.8%85.5%
Operating margin-61.2%33.1%
Net margin-67.4%30.7%
Free cash flow (TTM)$-108.17M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership69.1%96.8%
Insider activity (12mo)33 buy / 17 sell28 buy / 22 sell
Short interest (% of float)17.7%1.9%
Analyst consensus100% buy (9)95% buy / 5% hold (21)
Analyst price target$14 (+259%)$624 (+21%)
StockVane view
StockVane Quant RatingE (7)C (68)
Company
Employees2986,400
Founded20181989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.